semaglutide and cardiovascular disease FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity Semaglutide and Cardiovascular Outcomes in

And obesity is not great for Alzheimer's risk

Even modest resistance trainingsuch as 2030 minutes twice weeklymay help reduce muscle loss compared to no strength training

Our results have revealed both the activation of AMPK and S6K in the VMH and LH in response to changes in glucose concentration or nutritional state, and that GLP-1/exendin-4 acts by counteracting the activation/inactivation of these kinases and contributing to the balance of proper AMPK and S6K activation

Some people report weight changes with lower doses, but results vary

3.5 Attenuation of intracellular ROS accumulation and modulation of MDA and SOD levels by GO@GSH-FA Fluorescence micrographs show the intracellular ROS levels in different treatment groups visualized using DCFH-DA as a fluorescent probe (Figure 5A)

is Metformin FDA-approved to treat type 2 diabetes, in combination with diet and exercise